2,038
Views
2
CrossRef citations to date
0
Altmetric
Editorial

In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers

, , &
Pages 735-738 | Received 20 Sep 2021, Accepted 31 Mar 2022, Published online: 15 Apr 2022

Figures & data

Figure 1. Mathematical model [Citation5,Citation6] based prediction on the impact of implementing human papillomavirus (HPV) vaccination with 80% coverage according to the girls-only (a and b) vs. gender-neutral (c and d) strategy on HPV16 incidence in women (left) and men (right) by age and calendar time (years).

Figure 1. Mathematical model [Citation5,Citation6] based prediction on the impact of implementing human papillomavirus (HPV) vaccination with 80% coverage according to the girls-only (a and b) vs. gender-neutral (c and d) strategy on HPV16 incidence in women (left) and men (right) by age and calendar time (years).

Figure 2. Incidence of invasive cervical cancer (/100,000 women) in Finnish fertile-aged women (<40 years of age) during 1953–2018 (NORDCAN 2.0 https://nordcan.iarc.fr/en/ Database version 9.0 accessed on 11/07/202 [Citation21]). The red dotted line indicates the cervical cancer elimination threshold specified by the WHO. The blue dots indicate the observed crude rate of each year.

Figure 2. Incidence of invasive cervical cancer (/100,000 women) in Finnish fertile-aged women (<40 years of age) during 1953–2018 (NORDCAN 2.0 https://nordcan.iarc.fr/en/ Database version 9.0 accessed on 11/07/202 [Citation21]). The red dotted line indicates the cervical cancer elimination threshold specified by the WHO. The blue dots indicate the observed crude rate of each year.

Table 1. Incidence (age-specific incidence rates per 100,000 women) of cervical cancer in 20–39-year-old Finnish women over 60 years (NORDCAN)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.